Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between$ 545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of$ 580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be He ...